Related Experiment Videos
Neuroinflammatory processes in Parkinson's disease.
Etienne C Hirsch1, Stéphane Hunot, Andreas Hartmann
1INSERM U675, Experimental Neurology and Therapeutics, Hôpital de la Salpêtrière, Paris, France. hirsch@ccr.jussieu.fr
Parkinsonism & Related Disorders
|May 12, 2005
Summary
Parkinson's disease involves the loss of dopamine neurons and glial cell activation. Inhibiting this glial reaction may offer a new therapeutic strategy to slow neurodegeneration.
Area of Science:
- Neuroscience
- Neuroimmunology
- Pathology
Background:
- Parkinson's disease (PD) is characterized by dopaminergic (DA) neuron loss in the substantia nigra (SN).
- This neuronal loss is accompanied by significant astrogliosis and microglial activation.
- Microglial activation is also observed in animal models of PD induced by various toxins like MPTP and rotenone.
Purpose of the Study:
- To investigate the role of glial cells in the propagation of neuronal degeneration in Parkinson's disease.
- To explore the potential of targeting glial reactions and inflammatory processes as a therapeutic strategy for PD.
Main Methods:
- Post-mortem examination of Parkinson's disease brains.
- Analysis of animal models of Parkinson's disease (MPTP, rotenone, annonacine, LPS).
- Review of recent evidence on disease progression and glial cell involvement.
Main Results:
- Confirmed association between dopaminergic neuron loss, astrogliosis, and microglial activation in PD.
- Microglial activation is a consistent finding in various PD models.
- Evidence suggests glial cells may release toxic substances contributing to disease progression.
Conclusions:
- Glial cells, particularly activated microglia, play a significant role in Parkinson's disease pathogenesis.
- The inflammatory response mediated by glial cells may drive ongoing neurodegeneration.
- Inhibiting glial activation and inflammation presents a promising therapeutic avenue for Parkinson's disease.